Journal of VitreoRetinal Diseases最新文献

{"title":"Resolution of Vitreomacular Traction Following a Commercial Flight Simulator Experience.","authors":"Nathaniel Ashby, Timothy Kaftan, Marc Ohlhausen, Sean Kim, Edward McGill, Steven Yeh","doi":"10.1177/24741264251366407","DOIUrl":"https://doi.org/10.1177/24741264251366407","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the effect of rotational forces on the vitreoretinal interface in a case of vitreomacular traction. <b>Methods:</b> Retrospective, observational case report. <b>Results:</b> A 66-year-old woman presented with symptomatic vitreomacular traction with reduced visual acuity to 20/60. Optical coherence tomography (OCT) indicated left eye vitreomacular traction. After discussion of treatment options including vitrectomy, the patient elected to proceed with a commercial flight simulator experience given her concerns regarding the risks of surgery or other invasive procedures. A repeat OCT 3 weeks later showed resolution of vitreomacular traction. Long-term follow-up visual acuity returned to 20/25 in the left eye. <b>Conclusions:</b> A separation of the vitreous from the fovea was observed following a commercial flight simulator experience. The machine's maneuverability and associated 3-dimensional acceleration potential allows force to traverse the vitreous at multiple vectors. It is hypothesized that force vectors perpendicular to the vitreomacular interface contributed to its separation.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251366407"},"PeriodicalIF":0.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indications and Outcomes of Select Vitreoretinal Surgery in Patients With Marfan Syndrome.","authors":"Lauren C Kiryakoza, Jesse D Sengillo, Natasha F S da Cruz, Joshua H Uhr, Justin Townsend, Audina M Berrocal, Jayanth Sridhar, Byron L Lam, William E Smiddy, Harry W Flynn","doi":"10.1177/24741264251362883","DOIUrl":"https://doi.org/10.1177/24741264251362883","url":null,"abstract":"<p><p><b>Purpose:</b> To report clinical indications and outcomes of select vitreoretinal surgery in patients with Marfan syndrome. <b>Methods:</b> A retrospective consecutive case series of patients with Marfan syndrome undergoing surgery was performed. Data collected included demographics, systemic and ocular history, refraction, and preoperative and postoperative examination findings. <b>Results:</b> Twenty-seven patients (39 eyes) with Marfan syndrome who underwent vitreoretinal surgery were included. Mean age at time of surgery was 37 years, and mean follow-up duration was 4 years. Surgical indications for patients with Marfan syndrome included visually significant crystalline lens subluxation (n = 25 eyes), rhegmatogenous retinal detachment (RRD) (n = 9 eyes), and dislocated intraocular lens implants (n = 5 eyes). Best-corrected visual acuity was 20/40 or better in 21 eyes undergoing surgery for lens subluxation. For patients undergoing surgery for RRD, anatomic reattachment was achieved by last follow-up in 8 eyes (89%). <b>Conclusions:</b> Pars plana lensectomy and vitrectomy for crystalline lens subluxation was the most common vitreoretinal surgery in patients with Marfan syndrome.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251362883"},"PeriodicalIF":0.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation Retinopathy After Whole-Brain Radiotherapy in a Patient With Pineal Gland Tumor.","authors":"Irina Sverdlichenko, Safwan Tayeb, Anarsaikhan Narmandakh, Edward Margolin, Derek S Tsang, Peng Yan","doi":"10.1177/24741264251359075","DOIUrl":"https://doi.org/10.1177/24741264251359075","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of radiation retinopathy following craniospinal radiation and provide an overview of studies on radiation retinopathy following whole-brain radiotherapy. <b>Methods:</b> A retrospective chart review was conducted to collect a single patient's data on demographics, radiation therapy, ophthalmologic examination findings, treatment, and outcomes. For the systematic review, OVID Medline, Embase, and Cochrane CENTRAL were searched for studies reporting on radiation retinopathy following whole-brain radiotherapy. <b>Results:</b> A 24-year-old man with a history of craniospinal radiation presented with proliferative maculopathy. Initial visual acuity was 20/150 in the right eye and 20/40 in the left eye. The patient received monthly intravitreal injections of bevacizumab followed by panretinal laser photocoagulation in both eyes. Maculopathy improved following treatment. Nine articles comprising 13 cases of radiation retinopathy following whole-brain radiotherapy (25 affected eyes; mean ± SD age, 43.3 ± 10.8 years; 46.2% male) were identified by systematic review. None of the patients had diabetes. Radiotherapy was indicated for primary central nervous system lymphoma (6 cases), metastatic spread of breast cancer (4 cases) or lung cancer (2 cases), and acute lymphocytic lymphoma (1 case). The median radiation dose received was 40.7 Gy (range, 30-50). Ten patients had received prior or concurrent chemotherapy. Median time from radiotherapy to symptom onset was 20.5 months (range, 2-216). More than half of patients developed retinopathy bilaterally. <b>Conclusions:</b> To our knowledge, this is the first systematic review to highlight the risk of radiation retinopathy following whole-brain radiotherapy, particularly the increased frequency in patients who have received chemotherapy.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359075"},"PeriodicalIF":0.8,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Central Subfield Thickness Fluctuations on Visual Outcomes in Neovascular Age-Related Macular Degeneration in the VIEW Trials.","authors":"Dilsher S Dhoot, Chirag P Shah, Fabiana Q Silva, April J McCullough, Weiming Du, Hadi Moini, Peter K Kaiser","doi":"10.1177/24741264251359902","DOIUrl":"https://doi.org/10.1177/24741264251359902","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the impact of central subfield thickness (CST) fluctuations on visual outcomes in treatment-naïve eyes with neovascular age-related macular degeneration from VIEW 1 and VIEW 2. <b>Methods:</b> Eyes were treated with intravitreal ranibizumab 0.5 mg every 4 weeks (Rq4) or aflibercept 2 mg every 4 or 8 weeks (2q4 or 2q8). The relationship between CST fluctuations and visual outcomes was evaluated via mixed model for repeated measures in quartiles of SDs of CST from baseline to week 52 (n = 1792; quartile 1: ≤27.6 µm; quartile 2: >27.6 to ≤42.5 µm; quartile 3: >42.5 to ≤65.3 µm; quartile 4: >65.3 µm) and weeks 12 to 52 (n = 1766; quartile 1: ≤27.0 µm; quartile 2: >27.0 to ≤43.2 µm; quartile 3: >43.2 to ≤67.8 µm; quartile 4: >67.8 µm). <b>Results:</b> Least squares mean best-corrected visual acuity (BCVA) gains from baseline to week 52 for quartile 1 to quartile 4 were 9.6, 10.1, 9.6, and 6.7 letters, respectively (quartile 4 vs quartile 1: nominal <i>P</i> = .0017). Least squares mean BCVA letter gains within each quartile treated with Rq4, 2q4, and 2q8, respectively, were 7.0, 10.3, and 10.2 (quartile 1); 11.3, 9.3, and 8.8 (quartile 2); 10.0, 9.3, and 10.1 (quartile 3); and 7.4, 8.4, and 6.2 (quartile 4). From weeks 12 to 52, least squares mean BCVA gains for quartile 1 to quartile 4 were 10.0, 9.7, 9.7, and 6.9 letters, respectively (quartile 4 vs quartile 1: nominal <i>P</i> = .0008). Least squares mean BCVA letter gains within each quartile treated with Rq4, 2q4, and 2q8, respectively, were 7.9, 10.7, and 10.6 (quartile 1); 10.7, 9.3, and 8.1 (quartile 2); 9.3, 9.5, and 10.9 (quartile 3); and 8.2, 8.0, and 6.4 (quartile 4). <b>Conclusions:</b> The highest CST fluctuation was associated with lower BCVA gains, irrespective of antivascular endothelial growth factor agent or regimen.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359902"},"PeriodicalIF":0.8,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose 0.01% Atropine Eye Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option.","authors":"Jeanette Du, Osama Sabbagh, Brian K Do, Jason M Huang, Joshua D Levinson, Alexander Melamud, Mohammed K Barazi, Mohsin H Ali","doi":"10.1177/24741264251364819","DOIUrl":"https://doi.org/10.1177/24741264251364819","url":null,"abstract":"<p><p><b>Purpose:</b> To assess whether topical low-dose 0.01% atropine eye drops effectively alleviate floater symptoms, as measured by scores from a modified National Eye Institute Visual Function Questionnaire. <b>Methods:</b> This is a retrospective case series conducted at the Retina Group of Washington. Adults with persistently symptomatic vitreous floaters and either vitreous syneresis without posterior vitreous detachment (PVD) or a history of PVD for at least 3 months were included. Subjects with significant vitreoretinal pathology, significant media opacity, anatomic narrow angles, or a history of pars plana vitrectomy (PPV) were excluded. Patients completed a modified National Eye Institute Visual Function Questionnaire before using topical low-dose 0.01% atropine eye drops once daily for 1 week. The same questionnaire was then completed after the 1-week period to assess treatment response. The primary outcome measure was satisfaction with the drops. <b>Results:</b> A total of 44 patients received 0.01% atropine eye drops prescribed for daily application in either 1 or both eyes. There were 22 patients who completed at least 7 days of consecutive drop use. Of these, 13 patients (59.1%) were \"satisfied\" or \"very satisfied\" with the drops, and 11 patients (50%) reported that they would continue using the medication. <b>Conclusions:</b> Low-dose 0.01% atropine eye drops may be an effective, noninvasive treatment option for select patients with persistently symptomatic vitreous floaters resulting from vitreous syneresis or PVD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251364819"},"PeriodicalIF":0.8,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response.","authors":"Nicholas R Bello, Robert C Wang, Joseph Boss, Michael Singer, Sophia Hopkins, Kiran Billawala, Christopher R Henry, Danny A Mammo","doi":"10.1177/24741264251365386","DOIUrl":"https://doi.org/10.1177/24741264251365386","url":null,"abstract":"<p><p><b>Purpose:</b> To examine the effect of suprachoroidal triamcinolone acetonide on intraocular pressure (IOP) in patients with a known history of glaucoma, ocular hypertension, or steroid response. <b>Methods:</b> This was a multicenter, retrospective cohort study examining patients with glaucoma, ocular hypertension, or a prior steroid response who received suprachoroidal triamcinolone acetonide between February 1, 2022, and December 31, 2023. Patient charts were reviewed to record IOP at the time of treatment with suprachoroidal triamcinolone acetonide and at follow-up. <b>Results:</b> Ten (17%) of 59 eyes experienced an IOP increase of 5 mm Hg or greater following suprachoroidal triamcinolone acetonide injection. At follow-up, 3 eyes (5%) were documented to have an IOP of greater than 25 mm Hg, and no eyes were found to have an IOP greater than 35 mm Hg. Notably, 30 (79%) of 38 eyes with a prior steroid response did not develop an IOP elevation of 5 mm Hg or higher. When removing eyes that had prior incisional glaucoma surgery, 17 (68%) of 25 eyes with prior steroid response still did not develop an IOP elevation of 5 mm Hg or greater. No eyes in this study required glaucoma surgery following suprachoroidal triamcinolone acetonide within the follow-up period. The mean follow-up from initial suprachoroidal triamcinolone acetonide to first visit was 42.0 days. <b>Conclusions:</b> This study examined patients who would be considered high-risk for intraocular steroid therapy. In this population, there was a lower tendency to have an IOP response following suprachoroidal triamcinolone acetonide compared with published rates of IOP elevation from intraocular steroids in eyes without a known steroid response. All patients receiving local corticosteroids should be monitored for IOP elevations.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251365386"},"PeriodicalIF":0.8,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publication Outcomes of Abstracts Presented at Meetings of the American Society of Retina Specialists.","authors":"Dane A Jester, Muhammad Z Chauhan, Ahmed F Shakarchi, Ahmed B Sallam","doi":"10.1177/24741264251362892","DOIUrl":"https://doi.org/10.1177/24741264251362892","url":null,"abstract":"<p><p><b>Purpose:</b> To assess the publication outcomes of abstracts presented at the American Society of Retina Specialists (ASRS) meetings and identify characteristics associated with a more favorable publication rate, impact factor, and time to publication. <b>Methods:</b> We recorded abstract characteristics for abstracts presented at the 2017 and 2018 ASRS meetings and conducted a PubMed search to identify matching publications. We used descriptive statistics, univariate χ² test, and multivariate logistic and linear regression to analyze outcomes and associations. <b>Results:</b> Of the 572 analyzed abstracts, 59.6% (341/572) were translated into publications, resulting in a median impact factor of 3.6 and time to publication of 466 days. Oral presentation, sample size greater than 100, and university affiliation for multivariate logistic regression predicted a higher publication rate, with odds ratios of 1.78 (95% CI, 1.19-2.65), 1.57 (95% CI, 1.03-2.38), and 1.56 (95% CI, 1.06-2.30), respectively. In multivariate linear regression, the presenting author holding an MD or DO credential was significantly related to faster time to publication. <b>Conclusions:</b> The publication rate was 59.6%, with an increased likelihood of publication for those with a university affiliation, sample size greater than 100, or oral presentation type.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251362892"},"PeriodicalIF":0.8,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous Retinal Transplant in Refractory Macular Holes.","authors":"Talal Al-Assil, Denise Vogt, Armin Wolf, Rami Madani, Ali Jaafar Haidar, Jeffrey Bloom, Sydney Les, Shahd Alshareef, Tarek Alasil","doi":"10.1177/24741264251358095","DOIUrl":"10.1177/24741264251358095","url":null,"abstract":"<p><p><b>Purpose:</b> To report the structural and functional outcomes of autologous neurosensory retinal transplant for closure of refractory macular holes (MHs) and to highlight the long-term follow-up findings. <b>Methods:</b> Nine eyes of 9 patients with full-thickness MH refractory to previous vitrectomy with internal limiting membrane (ILM) peeling and tamponade underwent pars plana vitrectomy, autologous retinal transplant with short-term perfluoro-n-octane heavy liquid, followed by gas tamponade. Patients were followed for 12.7 ± 10 months (range, 3-32 months). <b>Results:</b> Optical coherence tomography showed complete anatomic closure of the MH in 8 of 9 eyes (89%). Restoration of the outer retina and integration of the neurosensory retinal flap were noted in 5 eyes. The mean corrected Snellen visual acuity (VA) was 20/1600 and improved postoperatively to 20/200. The logMAR VA improved postoperatively from 1.9 ± 0.2 (range, 1.3-2) to 1.0 ± 0.3 (range, 0.59-1.3). Three grafts developed epiretinal membranes and were observed. Graft shrinkage over time was noted in 1 patient. One patient with a chronic large MH and previous panretinal photocoagulation (PRP) had a successful transplant from retinal tissue that had undergone PRP. One eye developed retinal detachment with proliferative vitreoretinopathy (PVR) that was managed with scleral buckle, PVR peeling, and silicone oil tamponade. This was followed by a successful repeat autologous retinal transplant from the detached nasal retina and nasal 120 degrees retinectomy. <b>Conclusions:</b> Autologous retinal transplant for large refractory MHs provides anatomic closure and safely improves VA.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251358095"},"PeriodicalIF":0.8,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Macular Hole Closure With Sub-Tenon Triamcinolone Acetonide.","authors":"Reza Azimi, Amr K Hassan, Elina Ghafari, Baruch D Kuppermann, Mitul C Mehta","doi":"10.1177/24741264251364009","DOIUrl":"10.1177/24741264251364009","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the efficacy and safety of sub-Tenon triamcinolone acetonide in the management of secondary full-thickness macular holes after vitreoretinal surgeries or traumatic injury. <b>Methods:</b> This case series includes 3 patients with secondary macular holes. All patients were treated with 40 mg sub-Tenon triamcinolone acetonide injections for macular holes. <b>Results:</b> Postinjection, the macular holes closed in 2 months, 2 weeks, and 1 month, respectively. Vision improved in all cases. The third patient experienced a significant increase in intraocular pressure, effectively managed with topical medications. No recurrence was observed at follow-up. <b>Conclusions:</b> Sub-Tenon triamcinolone acetonide is a promising therapeutic option for the management of secondary macular holes less than 200 µm in diameter, demonstrating efficacy in promoting hole closure and improving visual outcomes.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251364009"},"PeriodicalIF":0.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features and Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration and Pachychoroid Neovasculopathy.","authors":"Angsita Khaohoen, Yodpong Chantarasorn","doi":"10.1177/24741264251359847","DOIUrl":"10.1177/24741264251359847","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate differences in baseline characteristics, outcomes, and metrics of swept-source optical coherence tomography (SS-OCT) angiography between drusen-associated neovascular age-related macular degeneration (nAMD) vs pachychoroid neovasculopathy. <b>Methods:</b> This prospective cohort study enrolled 1 eye per patient with treatment-naïve nAMD or pachychoroid neovasculopathy who underwent 3 monthly bevacizumab injections followed by a treat-and-extend regimen for 12 months or longer. Eligible patients were classified into 2 groups: those with drusen-associated nAMD and those with pachychoroid neovasculopathy. Drusen-associated nAMD refers to macular neovascularization (MNV) or polypoidal lesions surrounded by subretinal drusenoid deposits or soft drusen 63 μm or larger in diameter. The outcomes were collected at baseline, 6 months, and 12 months. <b>Results:</b> Patients with drusen-bordering MNV (51 cases) were older (69.6 years vs 64.2 years) and had a smaller ratio of low-density to high-density lipoprotein cholesterol (1.85 vs 2.14), longer daily sleep hours (7.03 hours vs 6.07 hours), a smaller proportion of patients with a history of central serous chorioretinopathy (CSCR) (0% vs 12.5%), and smaller baseline central choroidal volume compared with those with pachychoroid neovasculopathy (57 cases). At 12 months, eyes with drusen exhibited a lower choroidal vascularity index, larger foveal thickness (327 µm vs 273 µm), and more antivascular endothelial growth factor injections per year (7.0 vs 5.2) compared with eyes with pachychoroid neovasculopathy. Regarding secondary outcomes, a closed-circuit vascular pattern was associated with persistent retinal fluid at study completion. <b>Conclusions:</b> Patients with pachychoroid neovasculopathy appear to carry some systemic risk factors for CSCR, whereas patients with drusen-related nAMD had inferior responses to bevacizumab monotherapy and greater choriocapillaris hypoperfusion (characterized by thinner choroidal volume and lower choroidal vascularity index values).</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359847"},"PeriodicalIF":0.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}